Trial · NCT03474107
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 22
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival (OS) | Enfortumab Vedotin 1.25 mg/kg | 12.88 | 95% Confidence Interval 10.58 to 15.21 | months | |
| Overall Survival (OS) | Chemotherapy | 8.97 | 95% Confidence Interval 8.05 to 10.74 | months | |
| Progression Free Survival on Study Therapy (PFS1) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | Enfortumab Vedotin 1.25 mg/kg | 5.55 | 95% Confidence Interval 5.32 to 5.82 | months | |
| Progression Free Survival on Study Therapy (PFS1) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | Chemotherapy | 3.71 | 95% Confidence Interval 3.52 to 3.94 | months | |
| Overall Response Rate (ORR) as Per RECIST V1.1 | Enfortumab Vedotin 1.25 mg/kg | 40.6 | 95% Confidence Interval 34.90 to 46.54 | percentage of participants | |
| Overall Response Rate (ORR) as Per RECIST V1.1 | Chemotherapy | 17.9 | 95% Confidence Interval 13.71 to 22.76 | percentage of participants | |
| Disease Control Rate (DCR) as Per RECIST V1.1 | Enfortumab Vedotin 1.25 mg/kg | 71.9 | 95% Confidence Interval 66.30 to 76.99 | percentage of participants | |
| Disease Control Rate (DCR) as Per RECIST V1.1 | Chemotherapy | 53.4 | 95% Confidence Interval 47.52 to 59.17 | percentage of participants | |
| Duration of Response (DOR) as Per RECIST V1.1 | Enfortumab Vedotin 1.25 mg/kg | 7.39 | 95% Confidence Interval 5.59 to 9.46 | months | |
| Duration of Response (DOR) as Per RECIST V1.1 | Chemotherapy | 8.11 | 95% Confidence Interval 5.65 to 9.56 | months | |
| Change From Baseline to Week 12 in European Organisation for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire Global Health Status (QL2 Score) | Enfortumab Vedotin 1.25 mg/kg | -2.30 | Standard Deviation 18.02 | score on a scale | |
| Change From Baseline to Week 12 in European Organisation for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire Global Health Status (QL2 Score) | Chemotherapy | -5.72 | Standard Deviation 16.04 | score on a scale | |
| Change From Baseline to Week 12 in EuroQOL 5-dimension 5-level Questionnaire [EQ-5D-5L] Visual Analog Scale (VAS) | Enfortumab Vedotin 1.25 mg/kg | -1.8 | Standard Deviation 16.6 | score on a scale | |
| Change From Baseline to Week 12 in EuroQOL 5-dimension 5-level Questionnaire [EQ-5D-5L] Visual Analog Scale (VAS) | Chemotherapy | -5.3 | Standard Deviation 14.5 | score on a scale | |
| Number of Participants With Treatment Emergent Adverse Events | Enfortumab Vedotin 1.25 mg/kg | 290 | participants | ||
| Number of Participants With Treatment Emergent Adverse Events | Chemotherapy | 288 | participants | ||
| Number of Participants With ECOG Performance Status | Enfortumab Vedotin 1.25 mg/kg | ECOG PS = 0 | 34 | participants | |
| Number of Participants With ECOG Performance Status | Chemotherapy | ECOG PS = 0 | 57 | participants | |
| Number of Participants With ECOG Performance Status | Enfortumab Vedotin 1.25 mg/kg | ECOG PS = 1 | 110 | participants | |
| Number of Participants With ECOG Performance Status | Chemotherapy | ECOG PS = 1 | 118 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03474107/results